Bosutinib - Histology

Relevant Publications

Issue Release: 2024

An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents.

Issue Release: 2024

Abelson Tyrosine Kinase Inhibitors in Parkinson\'s Disease and Lewy Body Dementia: A Systematic Review, Meta-analysis, and Meta-regression.

Issue Release: 2024

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia.

Issue Release: 2024

UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment.

Issue Release: 2024

Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.

Issue Release: 2024

Appraisal of folate functionalized bosutinib cubosomes against hepatic cancer cells: In-vitro, In-silico, and in-vivo pharmacokinetic study.

Issue Release: 2024

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain.

Issue Release: 2024

A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia.

Issue Release: 2024

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.

Issue Release: 2024

Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.

Issue Release: 2024

Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.

Issue Release: 2024

Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis.

Issue Release: 2024

A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).

Issue Release: 2024

Investigation of the Role of NLRP3 Inflammasome Activation in New-Generation BCR-ABL1 Tyrosine Kinase Inhibitors-Induced Hepatotoxicity.

Issue Release: 2024

Novel ABL1 mutation in a Moroccan CML patient with Imatinib resistance.

Issue Release: 2024

Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by SCORE2 algorithm.

Issue Release: 2024

Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.

Issue Release: 2024

Isolated knuckle hyperpigmentation associated with bosutinib.

Issue Release: 2024

Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.

Issue Release: 2024

What Can a Trichogram Diagnose?

What are the Signs of Stain Deterioration?

Are There Any Treatments for Mold Contamination in Histological Samples?

What Causes Acidophilia?

What is the Structure of the Stratum Pyramidale?

What is the Morphology of Endothelial Cells?

What is a Pathological State?

How does collaboration at the Salk Institute enhance histological research?

What Are the Challenges in Using Glass Slides?

Why Are Grants Important for Histological Research?

Bosutinib - Histology

What is Bosutinib?

Mechanism of Action

Histological Changes Induced by Bosutinib

Clinical Implications

Side Effects and Histological Impact

Histological Techniques for Monitoring

Future Directions

Relevant Publications

Partnered Content Networks

Relevant Topics